γ-Cyclodextrin hydrogel for the sustained release of josamycin for potential ocular application

Glaucoma is the leading cause of blindness worldwide. However, its surgical treatment, in particular via trabeculectomy, can be complicated by fibrosis. In current clinical practice, application of the drug, Mitomycin C, prevents or delays fibrosis, but can lead to additional side effects, such as b...

Full description

Saved in:
Bibliographic Details
Published inDrug delivery Vol. 31; no. 1; p. 2361168
Main Authors Huling, Jennifer, Oschatz, Stefan, Lange, Helge, Sterenczak, Katharina Anna, Stahnke, Thomas, Markhoff, Jana, Stachs, Oliver, Möller, Steffen, Undre, Nasrullah, Peil, Anita, Jünemann, Anselm, Grabow, Niels, Fuellen, Georg, Eickner, Thomas
Format Journal Article
LanguageEnglish
Published England Taylor & Francis Ltd 01.12.2024
Taylor & Francis
Taylor & Francis Group
Subjects
Animals
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - chemistry
Anti-Bacterial Agents - pharmacology
Antibiotics
Cross-Linking Reagents - chemistry
Delayed-Action Preparations
Drug Carriers - chemistry
drug delivery
Drug Delivery Systems - methods
Drug Liberation
fibrosis
gamma-Cyclodextrins - chemistry
Glaucoma
Glaucoma - drug therapy
Humans
hydrogel
Hydrogels
Hydrogels - chemistry
josamycin
Solubility
γ-cyclodextrin
γ-cyclodextrin
fibrosis
josamycin
drug delivery
hydrogel
glaucoma
Online AccessGet full text
ISSN1071-7544
1521-0464
1521-0464
DOI10.1080/10717544.2024.2361168

Cover

Abstract Glaucoma is the leading cause of blindness worldwide. However, its surgical treatment, in particular via trabeculectomy, can be complicated by fibrosis. In current clinical practice, application of the drug, Mitomycin C, prevents or delays fibrosis, but can lead to additional side effects, such as bleb leakage and hypotony. Previous drug screening and testing has identified the known antibiotic, josamycin, as a possible alternative antifibrotic medication with potentially fewer side effects. However, a suitable ocular delivery mechanism for the hydrophobic drug to the surgical site does not yet exist. Therefore, the focus of this paper is the development of an implantable drug delivery system for sustained delivery of josamycin after glaucoma surgery based on crosslinked γ-cyclodextrin. γ-Cyclodextrin is a commonly used solubilizer which was shown to complex with josamycin, drastically increasing the drug's solubility in aqueous solutions. A simple γ-cyclodextrin crosslinking method produced biocompatible hydrogels well-suited for implantation. The crosslinked γ - cyclodextrin retained the ability to form complexes with josamycin, resulting in a 4-fold higher drug loading efficiency when compared to linear dextran hydrogels, and prolonged drug release over 4 days.
AbstractList Glaucoma is the leading cause of blindness worldwide. However, its surgical treatment, in particular via trabeculectomy, can be complicated by fibrosis. In current clinical practice, application of the drug, Mitomycin C, prevents or delays fibrosis, but can lead to additional side effects, such as bleb leakage and hypotony. Previous drug screening and testing has identified the known antibiotic, josamycin, as a possible alternative antifibrotic medication with potentially fewer side effects. However, a suitable ocular delivery mechanism for the hydrophobic drug to the surgical site does not yet exist. Therefore, the focus of this paper is the development of an implantable drug delivery system for sustained delivery of josamycin after glaucoma surgery based on crosslinked γ-cyclodextrin. γ-Cyclodextrin is a commonly used solubilizer which was shown to complex with josamycin, drastically increasing the drug's solubility in aqueous solutions. A simple γ-cyclodextrin crosslinking method produced biocompatible hydrogels well-suited for implantation. The crosslinked γ - cyclodextrin retained the ability to form complexes with josamycin, resulting in a 4-fold higher drug loading efficiency when compared to linear dextran hydrogels, and prolonged drug release over 4 days.
Glaucoma is the leading cause of blindness worldwide. However, its surgical treatment, in particular via trabeculectomy, can be complicated by fibrosis. In current clinical practice, application of the drug, Mitomycin C, prevents or delays fibrosis, but can lead to additional side effects, such as bleb leakage and hypotony. Previous in silico drug screening and in vitro testing has identified the known antibiotic, josamycin, as a possible alternative antifibrotic medication with potentially fewer side effects. However, a suitable ocular delivery mechanism for the hydrophobic drug to the surgical site does not yet exist. Therefore, the focus of this paper is the development of an implantable drug delivery system for sustained delivery of josamycin after glaucoma surgery based on crosslinked γ-cyclodextrin. γ-Cyclodextrin is a commonly used solubilizer which was shown to complex with josamycin, drastically increasing the drug’s solubility in aqueous solutions. A simple γ-cyclodextrin crosslinking method produced biocompatible hydrogels well-suited for implantation. The crosslinked γ − cyclodextrin retained the ability to form complexes with josamycin, resulting in a 4-fold higher drug loading efficiency when compared to linear dextran hydrogels, and prolonged drug release over 4 days.
Glaucoma is the leading cause of blindness worldwide. However, its surgical treatment, in particular via trabeculectomy, can be complicated by fibrosis. In current clinical practice, application of the drug, Mitomycin C, prevents or delays fibrosis, but can lead to additional side effects, such as bleb leakage and hypotony. Previous in silico drug screening and in vitro testing has identified the known antibiotic, josamycin, as a possible alternative antifibrotic medication with potentially fewer side effects. However, a suitable ocular delivery mechanism for the hydrophobic drug to the surgical site does not yet exist. Therefore, the focus of this paper is the development of an implantable drug delivery system for sustained delivery of josamycin after glaucoma surgery based on crosslinked γ-cyclodextrin. γ-Cyclodextrin is a commonly used solubilizer which was shown to complex with josamycin, drastically increasing the drug’s solubility in aqueous solutions. A simple γ-cyclodextrin crosslinking method produced biocompatible hydrogels well-suited for implantation. The crosslinked γ − cyclodextrin retained the ability to form complexes with josamycin, resulting in a 4-fold higher drug loading efficiency when compared to linear dextran hydrogels, and prolonged drug release over 4 days.
Glaucoma is the leading cause of blindness worldwide. However, its surgical treatment, in particular via trabeculectomy, can be complicated by fibrosis. In current clinical practice, application of the drug, Mitomycin C, prevents or delays fibrosis, but can lead to additional side effects, such as bleb leakage and hypotony. Previous in silico drug screening and in vitro testing has identified the known antibiotic, josamycin, as a possible alternative antifibrotic medication with potentially fewer side effects. However, a suitable ocular delivery mechanism for the hydrophobic drug to the surgical site does not yet exist. Therefore, the focus of this paper is the development of an implantable drug delivery system for sustained delivery of josamycin after glaucoma surgery based on crosslinked γ-cyclodextrin. γ-Cyclodextrin is a commonly used solubilizer which was shown to complex with josamycin, drastically increasing the drug's solubility in aqueous solutions. A simple γ-cyclodextrin crosslinking method produced biocompatible hydrogels well-suited for implantation. The crosslinked γ - cyclodextrin retained the ability to form complexes with josamycin, resulting in a 4-fold higher drug loading efficiency when compared to linear dextran hydrogels, and prolonged drug release over 4 days.Glaucoma is the leading cause of blindness worldwide. However, its surgical treatment, in particular via trabeculectomy, can be complicated by fibrosis. In current clinical practice, application of the drug, Mitomycin C, prevents or delays fibrosis, but can lead to additional side effects, such as bleb leakage and hypotony. Previous in silico drug screening and in vitro testing has identified the known antibiotic, josamycin, as a possible alternative antifibrotic medication with potentially fewer side effects. However, a suitable ocular delivery mechanism for the hydrophobic drug to the surgical site does not yet exist. Therefore, the focus of this paper is the development of an implantable drug delivery system for sustained delivery of josamycin after glaucoma surgery based on crosslinked γ-cyclodextrin. γ-Cyclodextrin is a commonly used solubilizer which was shown to complex with josamycin, drastically increasing the drug's solubility in aqueous solutions. A simple γ-cyclodextrin crosslinking method produced biocompatible hydrogels well-suited for implantation. The crosslinked γ - cyclodextrin retained the ability to form complexes with josamycin, resulting in a 4-fold higher drug loading efficiency when compared to linear dextran hydrogels, and prolonged drug release over 4 days.
Author Jünemann, Anselm
Lange, Helge
Möller, Steffen
Oschatz, Stefan
Fuellen, Georg
Peil, Anita
Markhoff, Jana
Stachs, Oliver
Grabow, Niels
Undre, Nasrullah
Stahnke, Thomas
Sterenczak, Katharina Anna
Eickner, Thomas
Huling, Jennifer
Author_xml – sequence: 1
  givenname: Jennifer
  surname: Huling
  fullname: Huling, Jennifer
  organization: Institute for Biomedical Engineering, Rostock University Medical Center, Rostock, Germany
– sequence: 2
  givenname: Stefan
  surname: Oschatz
  fullname: Oschatz, Stefan
  organization: Institute for Biomedical Engineering, Rostock University Medical Center, Rostock, Germany
– sequence: 3
  givenname: Helge
  surname: Lange
  fullname: Lange, Helge
  organization: Institute for Biomedical Engineering, Rostock University Medical Center, Rostock, Germany
– sequence: 4
  givenname: Katharina Anna
  surname: Sterenczak
  fullname: Sterenczak, Katharina Anna
  organization: Department of Ophthalmology, Rostock University Medical Center, Rostock, Germany
– sequence: 5
  givenname: Thomas
  surname: Stahnke
  fullname: Stahnke, Thomas
  organization: Department of Ophthalmology, Rostock University Medical Center, Rostock, Germany
– sequence: 6
  givenname: Jana
  surname: Markhoff
  fullname: Markhoff, Jana
  organization: Institute for Biomedical Engineering, Rostock University Medical Center, Rostock, Germany
– sequence: 7
  givenname: Oliver
  surname: Stachs
  fullname: Stachs, Oliver
  organization: Department of Ophthalmology, Rostock University Medical Center, Rostock, Germany
– sequence: 8
  givenname: Steffen
  surname: Möller
  fullname: Möller, Steffen
  organization: Institute for Biostatistics and Informatics in Medicine and Ageing Research, Rostock University Medical Center, Rostock, Germany
– sequence: 9
  givenname: Nasrullah
  surname: Undre
  fullname: Undre, Nasrullah
  organization: Institute for Biostatistics and Informatics in Medicine and Ageing Research, Rostock University Medical Center, Rostock, Germany
– sequence: 10
  givenname: Anita
  surname: Peil
  fullname: Peil, Anita
  organization: Institute for Biostatistics and Informatics in Medicine and Ageing Research, Rostock University Medical Center, Rostock, Germany
– sequence: 11
  givenname: Anselm
  surname: Jünemann
  fullname: Jünemann, Anselm
  organization: Department of Ophthalmology, Rostock University Medical Center, Rostock, Germany
– sequence: 12
  givenname: Niels
  surname: Grabow
  fullname: Grabow, Niels
  organization: Institute for Biomedical Engineering, Rostock University Medical Center, Rostock, Germany, Department Life, Light & Matter (LLM), University of Rostock, Rostock, Germany
– sequence: 13
  givenname: Georg
  surname: Fuellen
  fullname: Fuellen, Georg
  organization: Institute for Biostatistics and Informatics in Medicine and Ageing Research, Rostock University Medical Center, Rostock, Germany
– sequence: 14
  givenname: Thomas
  surname: Eickner
  fullname: Eickner, Thomas
  organization: Institute for Biomedical Engineering, Rostock University Medical Center, Rostock, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38899440$$D View this record in MEDLINE/PubMed
BookMark eNqFkstu1DAUhi1URC_wCKBIbNik-B5bLBAacalUiQ2sjePYMx554mA7FfNcvAfPhNOZVrQbNrbl851f_7mcg5MxjhaAlwheIijgWwQ71DFKLzHE9SAcIS6egDPEMGoh5fSkvivTLtApOM95CyEUCLNn4JQIISWl8Az8-PO7Xe1NiIP9VZIfm81-SHFtQ-NiasrGNnnORfvRDk2ywepsm-iabcx6tzeVX7ApFjsWr0MTzRx0avQ0BW908XF8Dp46HbJ9cbwvwPdPH7-tvrTXXz9frT5ct4ZBXlpikHSEUtE76Dhz0vXUCKOZ6bQTrHNQuA5j3gsJa4lYaDZYMRjJDdJuQOQCXB10h6i3akp-p9NeRe3V7UdMa6VT8SZYxaQdKDTWEaIpk7SXBvWYEE4Qd9TgqvX-oDXN_c4OphaXdHgg-jAy-o1axxuFEJJIUFgV3hwVUvw521zUzmdjQ9CjjXNWBHZQYI7JYvz1I3Qb5zTWXqkapUzUpiyWXv1r6d7L3SQrwA6ASTHnZN09gqBaNkbdbYxaNkYdN6bmvXuUZ3y5nVytzIf_ZP8FFVrGxg
CitedBy_id crossref_primary_10_3390_gels11030177
Cites_doi 10.1016/S0014-3057(96)00123-1
10.1002/jps.2600611103
10.1089/jop.2013.0060
10.3390/pharmaceutics12030275
10.1016/j.survophthal.2012.01.008
10.1586/17469899.3.6.613
10.1016/j.survophthal.2008.08.002
10.1080/08820538.2019.1581820
10.5402/2012/673564
10.1016/j.carres.2012.09.018
10.1023/a:1011956327987
10.1007/978-94-011-5448-2_32
10.1097/ICU.0000000000000729
10.1097/IJG.0000000000000720
10.1007/s00347-022-01686-4
10.1097/00055735-200404000-00015
10.1167/iovs.15-16998
10.1007/s10792-020-01391-8
10.1016/j.ijpharm.2016.10.062
10.1016/j.ijpharm.2020.119452
10.1111/jphp.12549
10.1016/j.ijpharm.2005.05.042
10.3390/ijms222111748
10.3390/ijms222413516
10.1016/j.survophthal.2020.05.005
10.1016/j.carbpol.2021.118889
10.5012/bkcs.2013.34.7.2016
10.1016/0005-2744(81)90093-0
10.3109/01480541003734030
10.1016/j.jconrel.2020.01.057
10.1038/s41598-017-15954-w
10.1016/S0039-6257(03)00038-9
10.1016/j.exer.2015.03.021
10.3390/ijms21103579
10.3389/fbioe.2022.817391
10.1016/0378-5173(94)90080-9
10.1371/journal.pone.0172592
10.1016/j.exer.2014.02.020
10.1016/j.eurpolymj.2013.08.020
10.1016/j.exer.2012.04.015
10.1007/s00417-019-04251-z
10.1016/j.aopr.2023.09.001
10.1098/rsos.200441
10.1136/bjo.2008.140939
10.1007/s10439-011-0336-z
10.1021/ci700257y
10.1007/BF02381283
10.1136/bjophthalmol-2015-307223
10.5005/jp-journals-10028-1233
10.1016/j.ijpharm.2017.04.010
10.1016/0014-4835(75)90049-4
10.1016/j.eurpolymj.2010.06.014
ContentType Journal Article
Copyright 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2024 The Author(s)
Copyright_xml – notice: 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2024 The Author(s)
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88I
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
M0S
M2P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1080/10717544.2024.2361168
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Science Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ (Directory of Open Access Journals)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest Science Journals (Alumni Edition)
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE

Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ (Directory of Open Access Journals)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate J. Huling et al
EISSN 1521-0464
ExternalDocumentID oai_doaj_org_article_59ed40cef33a4594b9c1b2336316f4c2
PMC11191840
38899440
10_1080_10717544_2024_2361168
Genre Journal Article
GroupedDBID ---
00X
0YH
29G
36B
4.4
53G
5GY
7X7
88I
8FI
8FJ
AAYXX
ABDBF
ABUWG
ACGEJ
ACGFS
ACUHS
ADBBV
ADCVX
ADRBQ
ADXPE
AENEX
AFKRA
AFKVX
AJWEG
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
ARJSQ
AZQEC
BABNJ
BCNDV
BENPR
BLEHA
BPHCQ
BVXVI
CCPQU
CITATION
CS3
DU5
DWQXO
EAP
EBC
EBD
EBS
EMB
EMK
EMOBN
EPL
ESX
F5P
FYUFA
GNUQQ
GROUPED_DOAJ
H13
HCIFZ
HMCUK
HZ~
M2P
M4Z
MK0
O9-
OK1
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RPM
SV3
TDBHL
TFDNU
TFL
TFW
TUS
UKHRP
V1S
~1N
0VX
5VS
AALIY
AAPXX
AWYRJ
BVLLS
CAG
CGR
COF
CUY
CVF
DEIEU
DLVIE
DTRLO
ECM
EIF
EJD
HYE
M44
NPM
QRXOQ
3V.
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c506t-3c19f3448bf0f65f9fb4c8ca5c7af857f08f7226b89015228a5de8dc96c1afd13
IEDL.DBID 7X7
ISSN 1071-7544
1521-0464
IngestDate Wed Aug 27 01:11:01 EDT 2025
Thu Aug 21 18:33:31 EDT 2025
Fri Sep 05 10:52:17 EDT 2025
Mon Jun 30 12:12:17 EDT 2025
Thu Apr 03 07:09:02 EDT 2025
Tue Jul 01 03:07:33 EDT 2025
Thu Apr 24 23:11:15 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords γ-cyclodextrin
fibrosis
josamycin
drug delivery
hydrogel
glaucoma
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c506t-3c19f3448bf0f65f9fb4c8ca5c7af857f08f7226b89015228a5de8dc96c1afd13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Supplemental data for this article can be accessed online at https://doi.org/10.1080/10717544.2024.2361168.
OpenAccessLink https://www.proquest.com/docview/3134584482?pq-origsite=%requestingapplication%
PMID 38899440
PQID 3134584482
PQPubID 52922
ParticipantIDs doaj_primary_oai_doaj_org_article_59ed40cef33a4594b9c1b2336316f4c2
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11191840
proquest_miscellaneous_3070826231
proquest_journals_3134584482
pubmed_primary_38899440
crossref_primary_10_1080_10717544_2024_2361168
crossref_citationtrail_10_1080_10717544_2024_2361168
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-Dec
PublicationDateYYYYMMDD 2024-12-01
PublicationDate_xml – month: 12
  year: 2024
  text: 2024-Dec
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Philadelphia
PublicationTitle Drug delivery
PublicationTitleAlternate Drug Deliv
PublicationYear 2024
Publisher Taylor & Francis Ltd
Taylor & Francis
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis Ltd
– name: Taylor & Francis
– name: Taylor & Francis Group
References e_1_3_5_29_1
e_1_3_5_27_1
e_1_3_5_25_1
e_1_3_5_23_1
International Organization for Standardization. (e_1_3_5_15_1) 2021
e_1_3_5_44_1
e_1_3_5_46_1
e_1_3_5_48_1
e_1_3_5_3_1
e_1_3_5_40_1
e_1_3_5_42_1
e_1_3_5_9_1
e_1_3_5_21_1
International Organization for Standardization. (e_1_3_5_14_1) 2009
Osono T (e_1_3_5_31_1) 1971
e_1_3_5_5_1
e_1_3_5_7_1
e_1_3_5_18_1
e_1_3_5_16_1
e_1_3_5_37_1
e_1_3_5_35_1
e_1_3_5_12_1
e_1_3_5_33_1
e_1_3_5_56_1
e_1_3_5_58_1
e_1_3_5_50_1
e_1_3_5_52_1
e_1_3_5_54_1
e_1_3_5_10_1
e_1_3_5_28_1
e_1_3_5_26_1
e_1_3_5_24_1
e_1_3_5_22_1
RStudio Team. (e_1_3_5_39_1) 2020
e_1_3_5_45_1
e_1_3_5_47_1
e_1_3_5_49_1
e_1_3_5_2_1
e_1_3_5_41_1
e_1_3_5_43_1
e_1_3_5_8_1
e_1_3_5_20_1
e_1_3_5_4_1
e_1_3_5_6_1
e_1_3_5_17_1
e_1_3_5_38_1
e_1_3_5_13_1
e_1_3_5_36_1
e_1_3_5_11_1
e_1_3_5_34_1
e_1_3_5_55_1
e_1_3_5_57_1
e_1_3_5_19_1
e_1_3_5_51_1
e_1_3_5_53_1
e_1_3_5_32_1
e_1_3_5_30_1
References_xml – volume-title: ISO 10993-12 biological evaluation of medical devices: Part 5: Sample preparation and reference materials
  year: 2021
  ident: e_1_3_5_15_1
– ident: e_1_3_5_37_1
  doi: 10.1016/S0014-3057(96)00123-1
– ident: e_1_3_5_20_1
  doi: 10.1002/jps.2600611103
– ident: e_1_3_5_10_1
  doi: 10.1089/jop.2013.0060
– volume-title: ISO 10993-5 biological evaluation of medical devices: Part 5: Tests for in vitro cytotoxicity
  year: 2009
  ident: e_1_3_5_14_1
– ident: e_1_3_5_38_1
  doi: 10.3390/pharmaceutics12030275
– ident: e_1_3_5_45_1
  doi: 10.1016/j.survophthal.2012.01.008
– ident: e_1_3_5_58_1
  doi: 10.1586/17469899.3.6.613
– ident: e_1_3_5_44_1
  doi: 10.1016/j.survophthal.2008.08.002
– ident: e_1_3_5_5_1
  doi: 10.1080/08820538.2019.1581820
– ident: e_1_3_5_7_1
  doi: 10.5402/2012/673564
– ident: e_1_3_5_25_1
  doi: 10.1016/j.carres.2012.09.018
– ident: e_1_3_5_41_1
  doi: 10.1023/a:1011956327987
– ident: e_1_3_5_2_1
  doi: 10.1007/978-94-011-5448-2_32
– ident: e_1_3_5_54_1
  doi: 10.1097/ICU.0000000000000729
– ident: e_1_3_5_52_1
  doi: 10.1097/IJG.0000000000000720
– ident: e_1_3_5_12_1
  doi: 10.1007/s00347-022-01686-4
– ident: e_1_3_5_57_1
  doi: 10.1097/00055735-200404000-00015
– ident: e_1_3_5_13_1
  doi: 10.1167/iovs.15-16998
– ident: e_1_3_5_34_1
  doi: 10.1007/s10792-020-01391-8
– ident: e_1_3_5_42_1
  doi: 10.1016/j.ijpharm.2016.10.062
– ident: e_1_3_5_47_1
  doi: 10.1016/j.ijpharm.2020.119452
– ident: e_1_3_5_30_1
  doi: 10.1111/jphp.12549
– ident: e_1_3_5_23_1
  doi: 10.1016/j.ijpharm.2005.05.042
– ident: e_1_3_5_28_1
  doi: 10.3390/ijms222111748
– ident: e_1_3_5_22_1
  doi: 10.3390/ijms222413516
– ident: e_1_3_5_3_1
  doi: 10.1016/j.survophthal.2020.05.005
– ident: e_1_3_5_8_1
  doi: 10.1016/j.carbpol.2021.118889
– ident: e_1_3_5_56_1
  doi: 10.5012/bkcs.2013.34.7.2016
– ident: e_1_3_5_29_1
  doi: 10.1016/0005-2744(81)90093-0
– ident: e_1_3_5_46_1
  doi: 10.3109/01480541003734030
– ident: e_1_3_5_16_1
  doi: 10.1016/j.jconrel.2020.01.057
– ident: e_1_3_5_18_1
  doi: 10.1038/s41598-017-15954-w
– ident: e_1_3_5_33_1
– ident: e_1_3_5_19_1
  doi: 10.1016/S0039-6257(03)00038-9
– ident: e_1_3_5_43_1
  doi: 10.1016/j.exer.2015.03.021
– ident: e_1_3_5_11_1
  doi: 10.3390/ijms21103579
– ident: e_1_3_5_26_1
  doi: 10.3389/fbioe.2022.817391
– ident: e_1_3_5_21_1
  doi: 10.1016/0378-5173(94)90080-9
– ident: e_1_3_5_49_1
  doi: 10.1371/journal.pone.0172592
– ident: e_1_3_5_55_1
  doi: 10.1016/j.exer.2014.02.020
– ident: e_1_3_5_27_1
  doi: 10.1016/j.eurpolymj.2013.08.020
– ident: e_1_3_5_50_1
  doi: 10.1016/j.exer.2012.04.015
– ident: e_1_3_5_36_1
  doi: 10.1007/s00417-019-04251-z
– ident: e_1_3_5_32_1
  doi: 10.1016/j.aopr.2023.09.001
– ident: e_1_3_5_48_1
  doi: 10.1098/rsos.200441
– ident: e_1_3_5_35_1
  doi: 10.1136/bjo.2008.140939
– ident: e_1_3_5_9_1
  doi: 10.1007/s10439-011-0336-z
– ident: e_1_3_5_6_1
  doi: 10.1021/ci700257y
– ident: e_1_3_5_4_1
  doi: 10.1007/BF02381283
– start-page: 41
  volume-title: Drug action and drug resistance in bacteria
  year: 1971
  ident: e_1_3_5_31_1
– volume-title: RStudio: Integrated development for R [computer software]
  year: 2020
  ident: e_1_3_5_39_1
– ident: e_1_3_5_17_1
  doi: 10.1136/bjophthalmol-2015-307223
– ident: e_1_3_5_40_1
  doi: 10.5005/jp-journals-10028-1233
– ident: e_1_3_5_24_1
  doi: 10.1016/j.ijpharm.2017.04.010
– ident: e_1_3_5_51_1
  doi: 10.1016/0014-4835(75)90049-4
– ident: e_1_3_5_53_1
  doi: 10.1016/j.eurpolymj.2010.06.014
SSID ssj0008125
Score 2.3831866
Snippet Glaucoma is the leading cause of blindness worldwide. However, its surgical treatment, in particular via trabeculectomy, can be complicated by fibrosis. In...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 2361168
SubjectTerms Animals
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - chemistry
Anti-Bacterial Agents - pharmacology
Antibiotics
Cross-Linking Reagents - chemistry
Delayed-Action Preparations
Drug Carriers - chemistry
drug delivery
Drug Delivery Systems - methods
Drug Liberation
fibrosis
gamma-Cyclodextrins - chemistry
Glaucoma
Glaucoma - drug therapy
Humans
hydrogel
Hydrogels
Hydrogels - chemistry
josamycin
Solubility
γ-cyclodextrin
SummonAdditionalLinks – databaseName: DOAJ (Directory of Open Access Journals)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQbwIFGQn1VNM4thP7CBVVhQTqoZV6C44ftGhJqt30kN_F_-hv6kycbHcRUi9ccvBDmnhm7G_kmc-EfBBOBiWsZzpyxaQpDbNGehZlpQrkQrUV1g5_-14en8mv5-p846kvzAlL9MBp4Q6UCV7mLkQhrFRGNsbxphCiFLyM0o27b27yOZia9mA4tlTKNuQMKd7m2h2dH2AbNkFsWMBHlJwjz-rGqTSS9_8Lcf6dOLlxEh09Jo8mCEk_JdGfkAehfUr2ThIH9bBPT-9Kqlb7dI-e3LFTD8_Ij5s_7HBwCyxl75eXLb0Y_LL7GRYU4CsFOEhXqaYqeIoPqsApR7tIf3Ur-3twMB6HXXU9ZhmBFN2Yx0o37sGfk7OjL6eHx2x6ZoE5lZc9E46bKCBMa2IeSxVNbKTTzipX2ahVFXMdK0BpjUbsUBTaKh-0d6Z03EbPxQuy03ZteEWoLgB9KBnA6QPopjE6YAzmdTTI01ZlRM7LXLuJgxyfwljUfKIqnbVTo3bqSTsZ-biedpVIOO6b8Bl1uB6MHNpjA1hWPVlWfZ9lZWR3toB6cuxVLbjAm2Wpofv9uhtcEu9ZbBu6axgD2yhEbYCcM_IyGcxaEqEhwJUyz4jeMqUtUbd72suLkfabIxcfxOOv_8fPvSEPccFSYs4u2emX1-EtwKu-eTd60i3bUB5T
  priority: 102
  providerName: Directory of Open Access Journals
Title γ-Cyclodextrin hydrogel for the sustained release of josamycin for potential ocular application
URI https://www.ncbi.nlm.nih.gov/pubmed/38899440
https://www.proquest.com/docview/3134584482
https://www.proquest.com/docview/3070826231
https://pubmed.ncbi.nlm.nih.gov/PMC11191840
https://doaj.org/article/59ed40cef33a4594b9c1b2336316f4c2
Volume 31
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3NbtQwELZoe-GC-Ce0rIyEempoHNuJfUK0arVColqhVlpOIXHstmhJtpv0kOfiPXgmZvK3uwjBJQfHlkYej_2NPfMNIe-4EVbyNPeVY9IXOtJ-qkXuOxHLELlQ0xhzhz9fRNMr8Wku5_2FW9WHVQ57YrtR56XBO_Jjzjg-6QkVflje-Vg1Cl9X-xIaO2SPARLB0g3xfHS44LRri66Ch8N8JHobMnhUcIxt2AQeYggfHjGGbKsbZ1NL4f833Pln-OTGeXT-mDzqgST92Gn-CXlgi6fkcNYxUTdH9HKdWFUd0UM6W3NUN8_It18__dPGLDChvV7dFvSmyVfltV1QALEUQCGtuswqm1MsqwJnHS0d_V5W6Y_GQH_stixrjDUCKco2mpVuvIY_J1fnZ5enU78vtuAbGUS1zw3TjsP8Zi5wkXTaZcIok0oTp07J2AXKxYDVMoUIIgxVKnOrcqMjw1KXM_6C7BZlYV8RqkLAIFJYMH0rTJhpZdETy5XTyNYWe0QM05yYnokcC2IsEtYTlg7aSVA7Sa8dj7wfhy07Ko7_DThBHY6dkUm7bShX10lvmInUNheBsY7zVEgtMm1YFnIecRY5kN4jB8MKSHrzrpL1YvTI2_E3GCa-tqSFLe-hD2ym4LsBfvbIy27BjJJwBW6uEIFH1NZS2hJ1-09xe9OSfzNk5AOv_PW_5donD3EqusCbA7Jbr-7tG4BPdTYhO8HX6aS1lAnZOzm7mH2ZtFcRvwEsBhme
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbK9gAXxJtAASNBTw2NYztxDhWipdWWtqsV2kq9pYljt0VLsuymQvld3PkJ_CZm8tgHQnDqJQfHtkYeex72zDeEvOFaGMmTzFWWSVdEQeQmkchcK0LpIxZqEmLu8Mkg6J-KT2fybI387HJhMKyyk4m1oM4KjXfk25xxfNITyn8_-eZi1Sh8Xe1KaCRtaYVsp4YYaxM7jkz1HVy42c7hR-D3W98_2B_t9d22yoCrpReULtcsshwmTq1nA2kjmwqtdCJ1mFglQ-spG4KRkipUnb6vEpkZleko0CyxGeMw7y2yLvACpUfWd_cHw89zXQDqUzZRj8xFqLkuh0h529iGTeCj-vDhAWOI97qkHesiAn-zfP8M4FzSiAf3yN3WlKUfmr13n6yZ_AHZHDZY2NUWHS1Su2ZbdJMOFyjZ1UNy_uuHu1fpMabUl9OrnF5W2bS4MGMKZjQFs5TOmtwuk1Es7ALalhaWfilmyddKQ3_sNilKjHYCKoo6npYuvcc_Iqc3wojHpJcXuXlKqPLBCpLCgPAxQvtppAz6gpmyEeLFhQ4R3TLHusVCx5Ic45i1kKkdd2LkTtxyxyHv5sMmDRjI_wbsIg_nnRHLu24ophdxKxpiGZlMeNpYzhMhI5FGmqU-5wFngQXqHbLR7YC4FTCzeHEcHPJ6_htEA773JLkprqEPiHPwHsGCd8iTZsPMKeEKHG0hPIeola20Qurqn_zqsoYfZ4gJqIT37N90vSK3-6OT4_j4cHD0nNzBZWnCgDZIr5xemxdgzJXpy_bEUHJ-04f0N_VyWk0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%CE%B3-Cyclodextrin+hydrogel+for+the+sustained+release+of+josamycin+for+potential+ocular+application&rft.jtitle=Drug+delivery&rft.au=Huling%2C+Jennifer&rft.au=Oschatz%2C+Stefan&rft.au=Lange%2C+Helge&rft.au=Sterenczak%2C+Katharina+Anna&rft.date=2024-12-01&rft.pub=Taylor+%26+Francis+Ltd&rft.issn=1071-7544&rft.eissn=1521-0464&rft.volume=31&rft.issue=1&rft_id=info:doi/10.1080%2F10717544.2024.2361168
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1071-7544&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1071-7544&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1071-7544&client=summon